Beyond regulatory T cells: the potential role for IL-2 to deplete T-follicular helper cells and treat autoimmune diseases

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193(4257), 1007–1008 (1976).
  Medline CASGoogle Scholar
• 2 Wagner H, Hardt C, Heeg K, Rollinghoff M, Pfizenmaier K. T-cell-derived helper factor allows in vivo induction of cytotoxic T cells in nu/nu mice. Nature 284(5753), 278–278 (1980).
  Medline CASGoogle Scholar
• 3 Henney CS, Kuribayashi K, Kern DE, Gillis S. Interleukin-2 augments natural killer cell activity. Nature 291(5813), 335–338 (1981).
  Medline CASGoogle Scholar
• 4 Rosenberg SA. Raising the bar: the curative potential of human cancer immunotherapy. Sci. Transl. Med. 4(127), 127ps128 (2012).
  Google Scholar
• 5 Pett SL, Kelleher AD, Emery S. Role of interleukin-2 in patients with HIV infection. Drugs 70(9), 1115–1130 (2010).
  Medline CASGoogle Scholar
• 6 Schwartzentruber DJ, Lawson DH, Richards JM et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 364(22), 2119–2127 (2011).
  Medline CASGoogle Scholar
• 7 Rosenberg SA, Yannelli JR, Yang JC et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl Cancer Inst. 86(15), 1159–1166 (1994).
  Medline CASGoogle Scholar
• 8 Rosenberg SA, Yang JC, Sherry RM et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17(13), 4550–4557 (2011).
  Medline CASGoogle Scholar
• 9 Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155(3), 1151–1164 (1995).• First study characterizing Tregs.
  Medline CASGoogle Scholar
• 10 Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 30, 531–564 (2012).
  Medline CASGoogle Scholar
• 11 Williams MA, Tyznik AJ, Bevan MJ. Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature 441(7095), 890–893 (2006).
  Medline CASGoogle Scholar
• 12 Pipkin ME, Sacks JA, Cruz-Guilloty F, Lichtenheld MG, Bevan MJ, Rao A. Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity 32(1), 79–90 (2010).
  Medline CASGoogle Scholar
• 13 Kalia V, Sarkar S, Subramaniam S, Haining WN, Smith KA, Ahmed R. Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo. Immunity 32(1), 91–103 (2010).
  Medline CASGoogle Scholar
• 14 Lenardo MJ. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature 353(6347), 858–861 (1991).
  Medline CASGoogle Scholar
• 15 Liao W, Lin JX, Leonard WJ. IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr. Opin. Immunol. 23(5), 598–604 (2011).
  Medline CASGoogle Scholar
• 16 Laurence A, Tato CM, Davidson TS et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26(3), 371–381 (2007).
  Medline CASGoogle Scholar
• 17 Ballesteros-Tato A, Leon B, Graf BA et al. Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation. Immunity 36(5), 847–856 (2012).• Demonstrates that IL-2 administration prevents the development of T-follicular helper (Tfh) cells following influenza virus infection.
  Medline CASGoogle Scholar
• 18 Oestreich KJ, Mohn SE, Weinmann AS. Molecular mechanisms that control the expression and activity of Bcl-6 in TH1 cells to regulate flexibility with a TFH-like gene profile. Nat. Immunol. 13(4), 405–411 (2012).
  Medline CASGoogle Scholar
• 19 Johnston RJ, Choi YS, Diamond JA, Yang JA, Crotty S. STAT5 is a potent negative regulator of TFH cell differentiation. J. Exp. Med. 209(2), 243–250 (2012).
  Medline CASGoogle Scholar
• 20 Nurieva RI, Podd A, Chen Y et al. STAT5 protein negatively regulates T follicular helper (Tfh) cell generation and function. J. Biol. Chem. 287(14), 11234–11239 (2012).
  Medline CASGoogle Scholar
• 21 Leon B, Bradley JE, Lund FE, Randall TD, Ballesteros-Tato A. FoxP3+ regulatory T cells promote influenza-specific Tfh responses by controlling IL-2 availability. Nat. Commun. 5, 3495 (2014).
  Google Scholar
• 22 Crotty S. Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 29, 621–663 (2011).
  Medline CASGoogle Scholar
• 23 Suzuki H, Duncan GS, Takimoto H, Mak TW. Abnormal development of intestinal intraepithelial lymphocytes and peripheral natural killer cells in mice lacking the IL-2 receptor beta chain. J. Exp. Med. 185(3), 499–505 (1997).
  Medline CASGoogle Scholar
• 24 Sadlack B, Lohler J, Schorle H et al. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4⁺ T cells. Eur. J. Immunol. 25(11), 3053–3059 (1995).
  Medline CASGoogle Scholar
• 25 Suzuki H, Kundig TM, Furlonger C et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science 268(5216), 1472–1476 (1995).
  Medline CASGoogle Scholar
• 26 Sharfe N, Dadi HK, Shahar M, Roifman CM. Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor. Proc. Natl Acad. Sci. USA 94(7), 3168–3171 (1997).
  Medline CASGoogle Scholar
• 27 Caudy AA, Reddy ST, Chatila T, Atkinson JP, Verbsky JW. CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J. Allergy Clin. Immunol. 119(2), 482–487 (2007).
  Medline CASGoogle Scholar
• 28 Roifman CM. Human IL-2 receptor alpha chain deficiency. Pediatr. Res. 48(1), 6–11 (2000).
  Medline CASGoogle Scholar
• 29 Cheng G, Yu A, Dee MJ, Malek TR. IL-2R signaling is essential for functional maturation of regulatory T cells during thymic development. J. Immunol. 190(4), 1567–1575 (2013).
  Medline CASGoogle Scholar
• 30 Yuan X, Cheng G, Malek TR. The importance of regulatory T-cell heterogeneity in maintaining self-tolerance. Immunol. Rev. 259(1), 103–114 (2014).
  Medline CASGoogle Scholar
• 31 Saadoun D, Rosenzwajg M, Joly F et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N. Engl. J. Med. 365(22), 2067–2077 (2011).• Low-dose rIL-2 treatment significantly increases Tregs and improves vasculitis in patients with hepatitis C virus-induced vasculitis.
  Medline CASGoogle Scholar
• 32 Matsuoka K, Koreth J, Kim HT et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci. Transl. Med. 5(179), 179ra143 (2013).
  Google Scholar
• 33 Hartemann A, Bensimon G, Payan CA et al. Low-dose interleukin 2 in patients with type 1 diabetes: a Phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 1(4), 295–305 (2013).
  Medline CASGoogle Scholar
• 34 Kennedy-Nasser AA, Ku S, Castillo-Caro P et al. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin. Cancer Res. 20(8), 2215–2225 (2014).
  Medline CASGoogle Scholar
• 35 Baeyens A, Perol L, Fourcade G et al. Limitations of IL-2 and rapamycin in immunotherapy of type 1 diabetes. Diabetes 62(9), 3120–3131 (2013).
  Medline CASGoogle Scholar
• 36 Malek TR. The biology of interleukin-2. Annu. Rev. Immunol. 26, 453–479 (2008).
  Medline CASGoogle Scholar
• 37 Zelante T, Fric J, Wong AY, Ricciardi-Castagnoli P. Interleukin-2 production by dendritic cells and its immuno-regulatory functions. Front. Immunol. 3, 161 (2012).
  MedlineGoogle Scholar
• 38 Harris DP, Haynes L, Sayles PC et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat. Immunol. 1(6), 475–482 (2000).
  Medline CASGoogle Scholar
• 39 Wang X, Rickert M, Garcia KC. Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors. Science 310(5751), 1159–1163 (2005).
  Medline CASGoogle Scholar
• 40 Rickert M, Wang X, Boulanger MJ, Goriatcheva N, Garcia KC. The structure of interleukin-2 complexed with its alpha receptor. Science 308(5727), 1477–1480 (2005).
  Medline CASGoogle Scholar
• 41 Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38(1), 13–25 (2013).
  Medline CASGoogle Scholar
• 42 Brennan P, Babbage JW, Burgering BM, Groner B, Reif K, Cantrell DA. Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F. Immunity 7(5), 679–689 (1997).
  Medline CASGoogle Scholar
• 43 Walker SR, Nelson EA, Frank DA. STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas. Oncogene 26(2), 224–233 (2007).
  Medline CASGoogle Scholar
• 44 Fukao T, Koyasu S. Expression of functional IL-2 receptors on mature splenic dendritic cells. Eur. J. Immunol. 30(5), 1453–1457 (2000).
  Medline CASGoogle Scholar
• 45 Wuest SC, Edwan JH, Martin JF et al. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat. Med. 17(5), 604–609 (2011).
  Medline CASGoogle Scholar
• 46 Sabatos CA, Doh J, Chakravarti S et al. A synaptic basis for paracrine interleukin-2 signaling during homotypic T cell interaction. Immunity 29(2), 238–248 (2008).
  Medline CASGoogle Scholar
• 47 Huse M, Lillemeier BF, Kuhns MS, Chen DS, Davis MM. T cells use two directionally distinct pathways for cytokine secretion. Nat. Immunol. 7(3), 247–255 (2006).
  Medline CASGoogle Scholar
• 48 Granucci F, Feau S, Angeli V, Trottein F, Ricciardi-Castagnoli P. Early IL-2 production by mouse dendritic cells is the result of microbial-induced priming. J. Immunol. 170(10), 5075–5081 (2003).
  Medline CASGoogle Scholar
• 49 Kulhankova K, Rouse T, Nasr ME, Field EH. Dendritic cells control CD4⁺CD25⁺ Treg cell suppressor function in vitro through juxtacrine delivery of IL-2. PLoS ONE 7(9), e43609 (2012).
  Medline CASGoogle Scholar
• 50 Tokano Y, Murashima A, Takasaki Y, Hashimoto H, Okumura K, Hirose S. Relation between soluble interleukin 2 receptor and clinical findings in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 48(10), 803–809 (1989).
  Medline CASGoogle Scholar
• 51 Sawada S, Hashimoto H, Iijma S et al. Increased soluble IL-2 receptor in serum of patients with systemic lupus erythematosus. Clin. Rheumatol. 12(2), 204–209 (1993).
  Medline CASGoogle Scholar
• 52 Ward MM, Dooley MA, Christenson VD, Pisetsky DS. The relationship between soluble interleukin 2 receptor levels and antidouble stranded DNA antibody levels in patients with systemic lupus erythematosus. J. Rheumatol. 18(2), 235–240 (1991).
  Medline CASGoogle Scholar
• 53 Ter Borg EJ, Horst G, Limburg PC, Kallenberg CG. Changes in plasma levels of interleukin-2 receptor in relation to disease exacerbations and levels of anti-dsDNA and complement in systemic lupus erythematosus. Clin. Exp. Immunol. 82(1), 21–26 (1990).
  Medline CASGoogle Scholar
• 54 Maier LM, Lowe CE, Cooper J et al. IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genet. 5(1), e1000322 (2009).
  MedlineGoogle Scholar
• 55 Maier LM, Anderson DE, Severson CA et al. Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J. Immunol. 182(3), 1541–1547 (2009).
  Medline CASGoogle Scholar
• 56 Russell SE, Moore AC, Fallon PG, Walsh PT. Soluble IL-2Ralpha (sCD25) exacerbates autoimmunity and enhances the development of Th17 responses in mice. PLoS ONE 7(10), e47748 (2012).
  Medline CASGoogle Scholar
• 57 Bilate AM, Lafaille JJ. Induced CD4⁺Foxp3⁺ regulatory T cells in immune tolerance. Annu. Rev. Immunol. 30, 733–758 (2012).
  Medline CASGoogle Scholar
• 58 Abbas AK, Benoist C, Bluestone JA et al. Regulatory T cells: recommendations to simplify the nomenclature. Nat. Immunol. 14(4), 307–308 (2013).
  Medline CASGoogle Scholar
• 59 Bennett CL, Christie J, Ramsdell F et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27(1), 20–21 (2001).
  Medline CASGoogle Scholar
• 60 Wildin RS, Ramsdell F, Peake J et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet. 27(1), 18–20 (2001).
  Medline CASGoogle Scholar
• 61 Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8(2), 191–197 (2007).
  Medline CASGoogle Scholar
• 62 Brunkow ME, Jeffery EW, Hjerrild KA et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 27(1), 68–73 (2001).
  Medline CASGoogle Scholar
• 63 Malek TR, Yu A, Vincek V, Scibelli P, Kong L. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity 17(2), 167–178 (2002).
  Medline CASGoogle Scholar
• 64 Lio CW, Hsieh CS. A two-step process for thymic regulatory T cell development. Immunity 28(1), 100–111 (2008).
  Medline CASGoogle Scholar
• 65 Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6(11), 1142–1151 (2005).
  Medline CASGoogle Scholar
• 66 D'Cruz LM, Klein L. Development and function of agonist-induced CD25⁺Foxp3⁺ regulatory T cells in the absence of interleukin 2 signaling. Nat. Immunol. 6(11), 1152–1159 (2005).
  MedlineGoogle Scholar
• 67 Bayer AL, Yu A, Malek TR. Function of the IL-2R for thymic and peripheral CD4⁺CD25⁺ Foxp3⁺ T regulatory cells. J. Immunol. 178(7), 4062–4071 (2007).
  Medline CASGoogle Scholar
• 68 Zheng SG, Wang J, Wang P, Gray JD, Horwitz DA. IL-2 is essential for TGF-beta to convert naive CD4⁺CD25^- cells to CD25⁺Foxp3⁺ regulatory T cells and for expansion of these cells. J. Immunol. 178(4), 2018–2027 (2007).
  Medline CASGoogle Scholar
• 69 Davidson TS, Dipaolo RJ, Andersson J, Shevach EM. Cutting Edge: IL-2 is essential for TGF-beta-mediated induction of Foxp3⁺ T regulatory cells. J. Immunol. 178(7), 4022–4026 (2007).
  Medline CASGoogle Scholar
• 70 Burchill MA, Yang J, Vogtenhuber C, Blazar BR, Farrar MA. IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3⁺ regulatory T cells. J. Immunol. 178(1), 280–290 (2007).
  Medline CASGoogle Scholar
• 71 Yao Z, Kanno Y, Kerenyi M et al. Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood 109(10), 4368–4375 (2007).
  Medline CASGoogle Scholar
• 72 Vang KB, Yang J, Mahmud SA, Burchill MA, Vegoe AL, Farrar MA. IL-2, -7, and -15, but not thymic stromal lymphopoeitin, redundantly govern CD4⁺Foxp3⁺ regulatory T cell development. J. Immunol. 181(5), 3285–3290 (2008).
  Medline CASGoogle Scholar
• 73 Bayer AL, Lee JY, De La Barrera A, Surh CD, Malek TR. A function for IL-7R for CD4⁺CD25⁺Foxp3⁺ T regulatory cells. J. Immunol. 181(1), 225–234 (2008).
  Medline CASGoogle Scholar
• 74 Furtado GC, Curotto De Lafaille MA, Kutchukhidze N, Lafaille JJ. Interleukin 2 signaling is required for CD4(⁺) regulatory T cell function. J. Exp. Med. 196(6), 851–857 (2002).
  Medline CASGoogle Scholar
• 75 Yamanouchi J, Rainbow D, Serra P et al. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat. Genet. 39(3), 329–337 (2007).
  Medline CASGoogle Scholar
• 76 Brand OJ, Lowe CE, Heward JM et al. Association of the interleukin-2 receptor alpha (IL-2Ralpha)/CD25 gene region with Graves' disease using a multilocus test and tag SNPs. Clin. Endocrinol. 66(4), 508–512 (2007).
  Medline CASGoogle Scholar
• 77 Matesanz F, Fedetz M, Collado-Romero M et al. Allelic expression and interleukin-2 polymorphisms in multiple sclerosis. J. NeuroImmunol. 119(1), 101–105 (2001).
  Medline CASGoogle Scholar
• 78 Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447(7145), 661–678 (2007).
  MedlineGoogle Scholar
• 79 Vella A, Cooper JD, Lowe CE et al. Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms. Am. J. Hum. Genet. 76(5), 773–779 (2005).
  Medline CASGoogle Scholar
• 80 Lowe CE, Cooper JD, Brusko T et al. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat. Genet. 39(9), 1074–1082 (2007).
  Medline CASGoogle Scholar
• 81 Hafler DA, Compston A, Sawcer S et al. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 357(9), 851–862 (2007).
  Medline CASGoogle Scholar
• 82 Lieberman LA, Tsokos GC. The IL-2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity. J. BioMed. Biotechnol. 2010, 740619 (2010).
  MedlineGoogle Scholar
• 83 Hulme MA, Wasserfall CH, Atkinson MA, Brusko TM. Central role for interleukin-2 in type 1 diabetes. Diabetes 61(1), 14–22 (2012).
  Medline CASGoogle Scholar
• 84 Kitas GD, Salmon M, Farr M, Gaston JS, Bacon PA. Deficient interleukin 2 production in rheumatoid arthritis: association with active disease and systemic complications. Clin. Exp. Immunol. 73(2), 242–249 (1988).
  Medline CASGoogle Scholar
• 85 Roncarolo MG, Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat. Rev. Immunol. 7(8), 585–598 (2007).
  Medline CASGoogle Scholar
• 86 Grinberg-Bleyer Y, Baeyens A, You S et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J. Exp. Med. 207(9), 1871–1878 (2010).
  Medline CASGoogle Scholar
• 87 Koreth J, Matsuoka K, Kim HT et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N. Engl. J. Med. 365(22), 2055–2066 (2011).•• Demonstrates that patients with chronic graft-versus-host disease respond to low-dose IL-2 treatment.
  Medline CASGoogle Scholar
• 88 Churlaud G, Jimenez V, Ruberte J et al. Sustained stimulation and expansion of Tregs by IL2 control autoimmunity without impairing immune responses to infection, vaccination and cancer. Clin. Immunol. 151(2), 114–126 (2014).
  Medline CASGoogle Scholar
• 89 Humrich JY, Morbach H, Undeutsch R et al. Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc. Natl Acad. Sci. USA 107(1), 204–209 (2010).• Indicates that IL-2 shortage and autoimmune disease progression in lupus prone mice can be prevented by exogenous IL-2 administration.
  Medline CASGoogle Scholar
• 90 Tang Q, Henriksen KJ, Bi M et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. 199(11), 1455–1465 (2004).
  Medline CASGoogle Scholar
• 91 Tarbell KV, Yamazaki S, Olson K, Toy P, Steinman RM. CD25⁺ CD4⁺ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J. Exp. Med. 199(11), 1467–1477 (2004).
  Medline CASGoogle Scholar
• 92 Diaz-De-Durana Y, Lau J, Knee D et al. IL-2 immunotherapy reveals potential for innate beta cell regeneration in the non-obese diabetic mouse model of autoimmune diabetes. PLoS ONE 8(10), e78483 (2013).
  Medline CASGoogle Scholar
• 93 Tang Q, Adams JY, Penaranda C et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28(5), 687–697 (2008).• Demonstrates that administration of low doses of rIL2 prevented the onset of diabetes in young prediabetic-female non-obese diabetic mice.
  Medline CASGoogle Scholar
• 94 Dendrou CA, Plagnol V, Fung E et al. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat. Genet. 41(9), 1011–1015 (2009).
  Medline CASGoogle Scholar
• 95 Garg G, Tyler JR, Yang JH et al. Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4⁺CD25⁺ regulatory T cell function. J. Immunol. 188(9), 4644–4653 (2012).
  Medline CASGoogle Scholar
• 96 Wofsy D, Dauphinee MJ, Kipper SB, Talal N. Interleukin-2 deficiency in murine systemic lupus erythematosus. Transact. Assoc. Am. Phys. 94, 341–348 (1981).
  Medline CASGoogle Scholar
• 97 Solomou EE, Juang YT, Gourley MF, Kammer GM, Tsokos GC. Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J. Immunol. 166(6), 4216–4222 (2001).
  Medline CASGoogle Scholar
• 98 Linker-Israeli M, Bakke AC, Kitridou RC, Gendler S, Gillis S, Horwitz DA. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J. Immunol. 130(6), 2651–2655 (1983).
  Medline CASGoogle Scholar
• 99 Rabinovitch A, Suarez-Pinzon WL, Shapiro AM, Rajotte RV, Power R. Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes 51(3), 638–645 (2002).
  Medline CASGoogle Scholar
• 100 Yu A, Zhu L, Altman NH, Malek TR. A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity 30(2), 204–217 (2009).
  Medline CASGoogle Scholar
• 101 Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4⁺CD25⁺Foxp3⁺ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4⁺ T cells. Nat. Immunol. 8(12), 1353–1362 (2007).
  Medline CASGoogle Scholar
• 102 Ito S, Bollard CM, Carlsten M et al. Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers. Mol. Ther. 22(7), 1388–1395 (2014).
  Medline CASGoogle Scholar
• 103 Krieg C, Letourneau S, Pantaleo G, Boyman O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc. Natl Acad. Sci. USA 107(26), 11906–11911 (2010).• Demonstrates that antibody JES6-1, as the IL-2/JES6-1 complex, selectively targets CD25-expressing cells and expands Tregs more efficiently than IL-2 administration alone.
  Medline CASGoogle Scholar
• 104 Lee SY, Cho ML, Oh HJ et al. Interleukin-2/anti-interleukin-2 monoclonal antibody immune complex suppresses collagen-induced arthritis in mice by fortifying interleukin-2/STAT5 signalling pathways. Immunol. 137(4), 305–316 (2012).
  Medline CASGoogle Scholar
• 105 Webster KE, Walters S, Kohler RE et al. In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J. Exp. Med. 206(4), 751–760 (2009).
  Medline CASGoogle Scholar
• 106 Liu R, Zhou Q, La Cava A, Campagnolo DI, Van Kaer L, Shi FD. Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia. Eur. J. Immunol. 40(6), 1577–1589 (2010).
  Medline CASGoogle Scholar
• 107 Shapiro AM, Suarez-Pinzon WL, Power R, Rabinovitch A. Combination therapy with low dose sirolimus and tacrolimus is synergistic in preventing spontaneous and recurrent autoimmune diabetes in non-obese diabetic mice. Diabetologia 45(2), 224–230 (2002).
  Medline CASGoogle Scholar
• 108 Walsh PT, Buckler JL, Zhang J et al. PTEN inhibits IL-2 receptor-mediated expansion of CD4⁺ CD25⁺ Tregs. J. Clin. Invest. 116(9), 2521–2531 (2006).
  Medline CASGoogle Scholar
• 109 Long SA, Rieck M, Sanda S et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function. Diabetes 61(9), 2340–2348 (2012).
  Medline CASGoogle Scholar
• 110 Ballesteros-Tato A, Randall TD. Priming of T follicular helper cells by dendritic cells. Immunol. Cell Biol. 92(1), 22–27 (2014).
  Medline CASGoogle Scholar
• 111 Yu D, Rao S, Tsai LM et al. The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment. Immunity 31(3), 457–468 (2009).
  Medline CASGoogle Scholar
• 112 Nurieva RI, Chung Y, Martinez GJ et al. Bcl6 mediates the development of T follicular helper cells. Science 325(5943), 1001–1005 (2009).
  Medline CASGoogle Scholar
• 113 Johnston RJ, Poholek AC, Ditoro D et al. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science 325(5943), 1006–1010 (2009).
  Medline CASGoogle Scholar
• 114 Goodnow CC, Vinuesa CG, Randall KL, Mackay F, Brink R. Control systems and decision making for antibody production. Nat. Immunol. 11(8), 681–688 (2010).
  Medline CASGoogle Scholar
• 115 Han S, Hathcock K, Zheng B, Kepler TB, Hodes R, Kelsoe G. Cellular interaction in germinal centers. Roles of CD40 ligand and B7–2 in established germinal centers. J. Immunol. 155(2), 556–567 (1995).
  Medline CASGoogle Scholar
• 116 Linterman MA, Beaton L, Yu D et al. IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J. Exp. Med. 207(2), 353–363 (2010).
  Medline CASGoogle Scholar
• 117 Vogelzang A, Mcguire HM, Yu D, Sprent J, Mackay CR, King C. A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity 29(1), 127–137 (2008).
  Medline CASGoogle Scholar
• 118 Bryant VL, Ma CS, Avery DT et al. Cytokine-mediated regulation of human B cell differentiation into Ig-secreting cells: predominant role of IL-21 produced by CXCR5⁺ T follicular helper cells. J. Immunol. 179(12), 8180–8190 (2007).
  Medline CASGoogle Scholar
• 119 Allen CD, Okada T, Cyster JG. Germinal-center organization and cellular dynamics. Immunity 27(2), 190–202 (2007).
  Medline CASGoogle Scholar
• 120 Chang A, Henderson SG, Brandt D et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J. Immunol. 186(3), 1849–1860 (2011).
  Medline CASGoogle Scholar
• 121 Pugh-Bernard AE, Silverman GJ, Cappione AJ et al. Regulation of inherently autoreactive VH4–34 B cells in the maintenance of human B cell tolerance. J. Clin. Invest. 108(7), 1061–1070 (2001).
  Medline CASGoogle Scholar
• 122 Arce E, Jackson DG, Gill MA, Bennett LB, Banchereau J, Pascual V. Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J. Immunol. 167(4), 2361–2369 (2001).
  Medline CASGoogle Scholar
• 123 Grammer AC, Slota R, Fischer R et al. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J. Clin. Invest. 112(10), 1506–1520 (2003).
  Medline CASGoogle Scholar
• 124 Weyand CM, Goronzy JJ. Ectopic germinal center formation in rheumatoid synovitis. Ann. NY Acad. Sci. 987, 140–149 (2003).
  Medline CASGoogle Scholar
• 125 Ding Y, Li J, Wu Q et al. IL-17RA is essential for optimal localization of follicular Th cells in the germinal center light zone to promote autoantibody-producing B cells. J. Immunol. 191(4), 1614–1624 (2013).
  Medline CASGoogle Scholar
• 126 Luzina IG, Atamas SP, Storrer CE et al. Spontaneous formation of germinal centers in autoimmune mice. J. leukocyte Biol. 70(4), 578–584 (2001).
  Medline CASGoogle Scholar
• 127 Wang JH, New JS, Xie S et al. Extension of the germinal center stage of B cell development promotes autoantibodies in BXD2 mice. Arthritis Rheum. 65(10), 2703–2712 (2013).
  Medline CASGoogle Scholar
• 128 Kendall PL, Yu G, Woodward EJ, Thomas JW. Tertiary lymphoid structures in the pancreas promote selection of B lymphocytes in autoimmune diabetes. J. Immunol. 178(9), 5643–5651 (2007).
  Medline CASGoogle Scholar
• 129 Schroder AE, Greiner A, Seyfert C, Berek C. Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc. Natl Acad. Sci. USA 93(1), 221–225 (1996).
  Medline CASGoogle Scholar
• 130 Baumjohann D, Preite S, Reboldi A et al. Persistent antigen and germinal center B cells sustain T follicular helper cell responses and phenotype. Immunity 38(3), 596–605 (2013).
  Medline CASGoogle Scholar
• 131 Deenick EK, Chan A, Ma CS et al. Follicular helper T cell differentiation requires continuous antigen presentation that is independent of unique B cell signaling. Immunity 33(2), 241–253 (2010).
  Medline CASGoogle Scholar
• 132 Leon B, Ballesteros-Tato A, Browning JL, Dunn R, Randall TD, Lund FE. Regulation of T(H)2 development by CXCR5⁺ dendritic cells and lymphotoxin-expressing B cells. Nat. Immunol. 13(7), 681–690 (2012).
  Medline CASGoogle Scholar
• 133 Angeli V, Ginhoux F, Llodra J et al. B cell-driven lymphangiogenesis in inflamed lymph nodes enhances dendritic cell mobilization. Immunity 24(2), 203–215 (2006).
  Medline CASGoogle Scholar
• 134 Leon B, Ballesteros-Tato A, Misra RS, Wojciechowski W, Lund FE. Unraveling effector functions of B cells during infection: the hidden world beyond antibody production. Infect. Disord. Drug Targets 12(3), 213–221 (2012).
  Medline CASGoogle Scholar
• 135 Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 361(22), 2143–2152 (2009).
  Medline CASGoogle Scholar
• 136 Merrill JT, Neuwelt CM, Wallace DJ et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, Phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62(1), 222–233 (2010).
  Medline CASGoogle Scholar
• 137 Merrill J, Buyon J, Furie R et al. Assessment of flares in lupus patients enrolled in a Phase II/III study of rituximab (EXPLORER). Lupus 20(7), 709–716 (2011).
  Medline CASGoogle Scholar
• 138 Rovin BH, Furie R, Latinis K et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 64(4), 1215–1226 (2012).
  Medline CASGoogle Scholar
• 139 Sanz I, Lee FE. B cells as therapeutic targets in SLE. Nat. Rev. Rheumatol. 6(6), 326–337 (2010).
  Medline CASGoogle Scholar
• 140 Dilillo DJ, Hamaguchi Y, Ueda Y et al. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J. Immunol. 180(1), 361–371 (2008).
  Medline CASGoogle Scholar
• 141 Ahuja A, Anderson SM, Khalil A, Shlomchik MJ. Maintenance of the plasma cell pool is independent of memory B cells. Proc. Natl Acad. Sci. USA 105(12), 4802–4807 (2008).
  Medline CASGoogle Scholar
• 142 Bekar KW, Owen T, Dunn R et al. Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum. 62(8), 2443–2457 (2010).
  Medline CASGoogle Scholar
• 143 Ma CS, Deenick EK. Human T follicular helper (Tfh) cells and disease. Immunol. Cell Biol. 92(1), 64–71 (2013).
  MedlineGoogle Scholar
• 144 Tangye SG, Ma CS, Brink R, Deenick EK. The good, the bad and the ugly - TFH cells in human health and disease. Nat. Rev. Immunol. 13(6), 412–426 (2013).
  Medline CASGoogle Scholar
• 145 Simpson N, Gatenby PA, Wilson A et al. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum. 62(1), 234–244 (2010).
  Medline CASGoogle Scholar
• 146 Luo C, Li Y, Liu W et al. Expansion of circulating counterparts of follicular helper T cells in patients with myasthenia gravis. J. NeuroImmunol. 256(1–2), 55–61 (2013).
  Medline CASGoogle Scholar
• 147 Zhu C, Ma J, Liu Y et al. Increased frequency of follicular helper T cells in patients with autoimmune thyroid disease. J. Clin. Endocrinol. Metabol. 97(3), 943–950 (2012).
  Medline CASGoogle Scholar
• 148 Liu R, Wu Q, Su D et al. A regulatory effect of IL-21 on T follicular helper-like cell and B cell in rheumatoid arthritis. Arthritis Res. Ther. 14(6), R255 (2012).
  Medline CASGoogle Scholar
• 149 Ma J, Zhu C, Ma B et al. Increased frequency of circulating follicular helper T cells in patients with rheumatoid arthritis. Clin. Dev. Immunol. 2012, 827480 (2012).
  MedlineGoogle Scholar
• 150 Wang J, Shan Y, Jiang Z et al. High frequencies of activated B cells and T follicular helper cells are correlated with disease activity in patients with new-onset rheumatoid arthritis. Clin. Exp. Immunol. 174(2), 212–220 (2013).
  Medline CASGoogle Scholar
• 151 Xu X, Shi Y, Cai Y et al. Inhibition of increased circulating Tfh cell by anti-CD20 monoclonal antibody in patients with type 1 diabetes. PLoS ONE 8(11), e79858 (2013).
  MedlineGoogle Scholar
• 152 He J, Tsai LM, Leong YA et al. Circulating precursor CCR7(lo)PD-1(hi) CXCR5(⁺) CD4(⁺) T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure. Immunity 39(4), 770–781 (2013).
  Medline CASGoogle Scholar
• 153 Rankin AL, Guay H, Herber D et al. IL-21 receptor is required for the systemic accumulation of activated B and T lymphocytes in MRL/MpJ-Fas(lpr/lpr)/J mice. J. Immunol. 188(4), 1656–1667 (2012).
  Medline CASGoogle Scholar
• 154 Bubier JA, Sproule TJ, Foreman O et al. A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc. Natl Acad. Sci. USA 106(5), 1518–1523 (2009).
  Medline CASGoogle Scholar
• 155 Herber D, Brown TP, Liang S, Young DA, Collins M, Dunussi-Joannopoulos K. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R. Fc reduces disease progression. J. Immunol. 178(6), 3822–3830 (2007).
  Medline CASGoogle Scholar
• 156 Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4⁺CD25⁺ T cell-mediated suppression by dendritic cells. Science 299(5609), 1033–1036 (2003).
  Medline CASGoogle Scholar
• 157 Choi YS, Eto D, Yang JA, Lao C, Crotty S. Cutting edge: STAT1 is required for IL-6-mediated Bcl6 induction for early follicular helper cell differentiation. J. Immunol. 190(7), 3049–3053 (2013).
  Medline CASGoogle Scholar
• 158 Harker JA, Lewis GM, Mack L, Zuniga EI. Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection. Science 334(6057), 825–829 (2011).
  Medline CASGoogle Scholar
• 159 Nakayamada S, Poholek AC, Lu KT et al. Type I IFN induces binding of STAT1 to Bcl6: divergent roles of STAT family transcription factors in the T follicular helper cell genetic program. J. Immunol. 192(5), 2156–2166 (2014).
  Medline CASGoogle Scholar
• 160 Nurieva RI, Chung Y, Hwang D et al. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity 29(1), 138–149 (2008).
  Medline CASGoogle Scholar